Patents by Inventor Pia Pauliina Yachi

Pia Pauliina Yachi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-1 agonist antibodies and uses thereof
    Patent number: 10493148
    Abstract: The present invention relates to anti-human PD-1 agonist antibodies, and uses thereof for treating autoimmune disorders such as rheumatoid arthritis or for decreasing rejection of transplanted cells and/or tissues.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 3, 2019
    Assignee: Eli Lilly and Company
    Inventors: Pia Pauliina Yachi, Qing Chai, Yiqing Feng, Kristin Paige Newburn, Stephanie Marie Truhlar, Petra Verdino
  • PD-1 AGONIST ANTIBODIES AND USES THEREOF
    Publication number: 20190270818
    Abstract: The present invention relates to anti-human PD-1 agonist antibodies, and uses thereof for treating autoimmune disorders such as rheumatoid arthritis or for decreasing rejection of transplanted cells and/or tissues.
    Type: Application
    Filed: February 22, 2019
    Publication date: September 5, 2019
    Inventors: Pia Pauliina Yachi, Qing Chai, Yiqing Feng, Kristin Paige Newburn, Stephanie Marie Truhlar, Petra Verdino
  • Anti-TNF-anti-IL-17 bispecific antibodies
    Patent number: 9416182
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: August 16, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • Multifunctional antibodies binding to EGFR and MET
    Patent number: 9328173
    Abstract: Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 3, 2016
    Assignee: Eli Lilly and Company
    Inventors: Hector Aldaz, Barrett Allan, Ling Liu, Jirong Lu, Ying Tang, Sheng-Hung Rainbow Tschang, Pia Pauliina Yachi
  • Multifunctional Antibodies Binding to EGFR and MET
    Publication number: 20150175708
    Abstract: Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 25, 2015
    Inventors: Hector ALDAZ, Barrett ALLAN, Ling LIU, Jirong LU, Ying TANG, Sheng-Hung Rainbow TSCHANG, Pia Pauliina YACHI
  • ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES
    Publication number: 20140255406
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • Anti-hepcidin-25 selective antibodies and uses thereof
    Patent number: 8609817
    Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: December 17, 2013
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Peng Luan, Ying Tang, Derrick Ryan Witcher, Pia Pauliina Yachi
  • ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF
    Publication number: 20110189190
    Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.
    Type: Application
    Filed: July 29, 2009
    Publication date: August 4, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Donmienne Doen Mun Leung, Peng Luan, Ying Tang, Derrick Ryan Witcher, Pia Pauliina Yachi